Skip to main content
Top
Published in: Netherlands Heart Journal 12/2013

Open Access 01-12-2013 | ICIN

ENerGetIcs in hypertrophic cardiomyopathy: traNslation between MRI, PET and cardiac myofilament function (ENGINE study)

Authors: A. Güçlü, T. Germans, E. R. Witjas-Paalberends, G. J. M. Stienen, W. P. Brouwer, H. J. Harms, J. T. Marcus, A. B. A. Vonk, W. Stooker, A. Yilmaz, P. Klein, J. M. ten Berg, J. Kluin, F. W. Asselbergs, A. A. Lammertsma, P. Knaapen, A. C. van Rossum, J. van der Velden

Published in: Netherlands Heart Journal | Issue 12/2013

Login to get access

Abstract

Introduction

Hypertrophic cardiomyopathy (HCM) is an autosomal dominant heart disease mostly due to mutations in genes encoding sarcomeric proteins. HCM is characterised by asymmetric hypertrophy of the left ventricle (LV) in the absence of another cardiac or systemic disease. At present it lacks specific treatment to prevent or reverse cardiac dysfunction and hypertrophy in mutation carriers and HCM patients. Previous studies have indicated that sarcomere mutations increase energetic costs of cardiac contraction and cause myocardial dysfunction and hypertrophy. By using a translational approach, we aim to determine to what extent disturbances of myocardial energy metabolism underlie disease progression in HCM.

Methods

Hypertrophic obstructive cardiomyopathy (HOCM) patients and aortic valve stenosis (AVS) patients will undergo a positron emission tomography (PET) with acetate and cardiovascular magnetic resonance imaging (CMR) with tissue tagging before and 4 months after myectomy surgery or aortic valve replacement + septal biopsy. Myectomy tissue or septal biopsy will be used to determine efficiency of sarcomere contraction in-vitro, and results will be compared with in-vivo cardiac performance. Healthy subjects and non-hypertrophic HCM mutation carriers will serve as a control group.

Endpoints

Our study will reveal whether perturbations in cardiac energetics deteriorate during disease progression in HCM and whether these changes are attributed to cardiac remodelling or the presence of a sarcomere mutation per se. In-vitro studies in hypertrophied cardiac muscle from HOCM and AVS patients will establish whether sarcomere mutations increase ATP consumption of sarcomeres in human myocardium. Our follow-up imaging study in HOCM and AVS patients will reveal whether impaired cardiac energetics are restored by cardiac surgery.
Literature
1.
go back to reference Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002;287:1308–20.PubMed Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002;287:1308–20.PubMed
2.
go back to reference Marian AJ. Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. Lancet. 2000;355:58–60.PubMedCrossRef Marian AJ. Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. Lancet. 2000;355:58–60.PubMedCrossRef
3.
go back to reference Hoskins AC, Jacques A, Bardswell SC, et al. Normal passive viscoelasticity but abnormal myofibrillar force generation in human hypertrophic cardiomyopathy. J Mol Cell Cardiol. 2010;49:737–45.PubMedCrossRef Hoskins AC, Jacques A, Bardswell SC, et al. Normal passive viscoelasticity but abnormal myofibrillar force generation in human hypertrophic cardiomyopathy. J Mol Cell Cardiol. 2010;49:737–45.PubMedCrossRef
4.
go back to reference Kraft T, Witjas-Paalberends ER, Boontje NM, et al. Familial hypertrophic cardiomyopathy: functional effects of myosin mutation R723G in cardiomyocytes. J Mol Cell Cardiol. 2013;57:13–22.PubMedCrossRef Kraft T, Witjas-Paalberends ER, Boontje NM, et al. Familial hypertrophic cardiomyopathy: functional effects of myosin mutation R723G in cardiomyocytes. J Mol Cell Cardiol. 2013;57:13–22.PubMedCrossRef
5.
go back to reference van Dijk SJ, Dooijes D, dos Remedios CG, et al. Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction. Circulation. 2009;119:1473–83.PubMedCrossRef van Dijk SJ, Dooijes D, dos Remedios CG, et al. Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction. Circulation. 2009;119:1473–83.PubMedCrossRef
6.
go back to reference van Dijk SJ, Paalberends ER, Najafi A, et al. Contractile dysfunction irrespective of the mutant protein in human hypertrophic cardiomyopathy with normal systolic function. Circ Heart Fail. 2012;5:36–46.PubMedCrossRef van Dijk SJ, Paalberends ER, Najafi A, et al. Contractile dysfunction irrespective of the mutant protein in human hypertrophic cardiomyopathy with normal systolic function. Circ Heart Fail. 2012;5:36–46.PubMedCrossRef
7.
go back to reference Witjas-Paalberends ER, Piroddi N, Stam K, et al. Mutations in MYH7 reduce the force generating capacity of sarcomeres in human familial hypertrophic cardiomyopathy. Cardiovasc Res. 2013;99:432–41.PubMedCrossRef Witjas-Paalberends ER, Piroddi N, Stam K, et al. Mutations in MYH7 reduce the force generating capacity of sarcomeres in human familial hypertrophic cardiomyopathy. Cardiovasc Res. 2013;99:432–41.PubMedCrossRef
8.
go back to reference Belus A, Piroddi N, Scellini B, et al. The familial hypertrophic cardiomyopathy-associated myosin mutation R403Q accelerates tension generation and relaxation of human cardiac myofibrils. J Physiol. 2008;586:3639–44.PubMed Belus A, Piroddi N, Scellini B, et al. The familial hypertrophic cardiomyopathy-associated myosin mutation R403Q accelerates tension generation and relaxation of human cardiac myofibrils. J Physiol. 2008;586:3639–44.PubMed
9.
go back to reference Elliott K, Watkins H, Redwood CS. Altered regulatory properties of human cardiac troponin I mutants that cause hypertrophic cardiomyopathy. J Biol Chem. 2000;275:22069–74.PubMedCrossRef Elliott K, Watkins H, Redwood CS. Altered regulatory properties of human cardiac troponin I mutants that cause hypertrophic cardiomyopathy. J Biol Chem. 2000;275:22069–74.PubMedCrossRef
10.
go back to reference Ho CY, Sweitzer NK, McDonough B, et al. Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation. 2002;105:2992–7.PubMedCrossRef Ho CY, Sweitzer NK, McDonough B, et al. Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation. 2002;105:2992–7.PubMedCrossRef
11.
go back to reference Sequeira V, Wijnker PJ, Nijenkamp LL, et al. Perturbed length-dependent activation in human hypertrophic cardiomyopathy with missense sarcomeric gene mutations. Circ Res. 2013;112:1491–505.PubMedCrossRef Sequeira V, Wijnker PJ, Nijenkamp LL, et al. Perturbed length-dependent activation in human hypertrophic cardiomyopathy with missense sarcomeric gene mutations. Circ Res. 2013;112:1491–505.PubMedCrossRef
12.
go back to reference Ashrafian H, Redwood C, Blair E. Hypertrophic cardiomyopathy:a paradigm for myocardial energy depletion. Trends Genet. 2003;19:263–8.PubMedCrossRef Ashrafian H, Redwood C, Blair E. Hypertrophic cardiomyopathy:a paradigm for myocardial energy depletion. Trends Genet. 2003;19:263–8.PubMedCrossRef
13.
go back to reference Spindler M, Saupe KW, Christe ME, et al. Diastolic dysfunction and altered energetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy. J Clin Invest. 1998;101:1775–83.PubMedCrossRef Spindler M, Saupe KW, Christe ME, et al. Diastolic dysfunction and altered energetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy. J Clin Invest. 1998;101:1775–83.PubMedCrossRef
14.
go back to reference Javadpour MM, Tardiff JC, Pinz I, et al. Decreased energetics in murine hearts bearing the R92Q mutation in cardiac troponin T. J Clin Invest. 2003;112:768–75.PubMed Javadpour MM, Tardiff JC, Pinz I, et al. Decreased energetics in murine hearts bearing the R92Q mutation in cardiac troponin T. J Clin Invest. 2003;112:768–75.PubMed
15.
go back to reference Montgomery DE, Tardiff JC, Chandra M. Cardiac troponin T mutations: correlation between the type of mutation and the nature of myofilament dysfunction in transgenic mice. J Physiol. 2001;536:583–92.PubMedCrossRef Montgomery DE, Tardiff JC, Chandra M. Cardiac troponin T mutations: correlation between the type of mutation and the nature of myofilament dysfunction in transgenic mice. J Physiol. 2001;536:583–92.PubMedCrossRef
16.
go back to reference Crilley JG, Boehm EA, Blair E, et al. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol. 2003;41:1776–82.PubMedCrossRef Crilley JG, Boehm EA, Blair E, et al. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol. 2003;41:1776–82.PubMedCrossRef
17.
go back to reference Timmer SA, Germans T, Brouwer WP, et al. Carriers of the hypertrophic cardiomyopathy MYBPC3 mutation are characterized by reduced myocardial efficiency in the absence of hypertrophy and microvascular dysfunction. Eur J Heart Fail. 2011;13:1283–9.PubMedCrossRef Timmer SA, Germans T, Brouwer WP, et al. Carriers of the hypertrophic cardiomyopathy MYBPC3 mutation are characterized by reduced myocardial efficiency in the absence of hypertrophy and microvascular dysfunction. Eur J Heart Fail. 2011;13:1283–9.PubMedCrossRef
18.
go back to reference Abozguia K, Elliott P, McKenna W, et al. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation. 2010;122:1562–9.PubMedCrossRef Abozguia K, Elliott P, McKenna W, et al. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation. 2010;122:1562–9.PubMedCrossRef
19.
go back to reference Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Int J Cardiovasc Imaging. 2002;18:539–42.PubMed Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Int J Cardiovasc Imaging. 2002;18:539–42.PubMed
20.
go back to reference Knaapen P, Germans T, Knuuti J, et al. Myocardial energetics and efficiency: current status of the noninvasive approach. Circulation. 2007;115:918–27.PubMedCrossRef Knaapen P, Germans T, Knuuti J, et al. Myocardial energetics and efficiency: current status of the noninvasive approach. Circulation. 2007;115:918–27.PubMedCrossRef
21.
go back to reference Narolska NA, van Loon RB, Boontje NM, et al. Myocardial contraction is 5-fold more economical in ventricular than in atrial human tissue. Cardiovasc Res. 2005;65:221–9.PubMedCrossRef Narolska NA, van Loon RB, Boontje NM, et al. Myocardial contraction is 5-fold more economical in ventricular than in atrial human tissue. Cardiovasc Res. 2005;65:221–9.PubMedCrossRef
Metadata
Title
ENerGetIcs in hypertrophic cardiomyopathy: traNslation between MRI, PET and cardiac myofilament function (ENGINE study)
Authors
A. Güçlü
T. Germans
E. R. Witjas-Paalberends
G. J. M. Stienen
W. P. Brouwer
H. J. Harms
J. T. Marcus
A. B. A. Vonk
W. Stooker
A. Yilmaz
P. Klein
J. M. ten Berg
J. Kluin
F. W. Asselbergs
A. A. Lammertsma
P. Knaapen
A. C. van Rossum
J. van der Velden
Publication date
01-12-2013
Publisher
Bohn Stafleu van Loghum
Published in
Netherlands Heart Journal / Issue 12/2013
Print ISSN: 1568-5888
Electronic ISSN: 1876-6250
DOI
https://doi.org/10.1007/s12471-013-0478-8

Other articles of this Issue 12/2013

Netherlands Heart Journal 12/2013 Go to the issue

Editor's comment

Let’s talk about sex